<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medchrome &#187; Presentations</title>
	<atom:link href="http://medchrome.com/category/downloads/presentations/feed/" rel="self" type="application/rss+xml" />
	<link>http://medchrome.com</link>
	<description>Online Medical Magazine</description>
	<lastBuildDate>Tue, 07 Sep 2010 12:40:26 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Meningitis : Causative Agents and Lab diagnosis</title>
		<link>http://medchrome.com/basic-science/meningitis-causative-agents-and-lab-diagnosis/</link>
		<comments>http://medchrome.com/basic-science/meningitis-causative-agents-and-lab-diagnosis/#comments</comments>
		<pubDate>Wed, 25 Aug 2010 14:17:18 +0000</pubDate>
		<dc:creator>Sulav Shrestha</dc:creator>
				<category><![CDATA[Basic Sc.]]></category>
		<category><![CDATA[Microbiology]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[causes]]></category>
		<category><![CDATA[csf analysis]]></category>
		<category><![CDATA[kernig sign]]></category>
		<category><![CDATA[meningitis]]></category>
		<category><![CDATA[neck rigidity]]></category>
		<category><![CDATA[sepsis]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=1664</guid>
		<description><![CDATA[Presentation on Etiological factors and Laboratory Diagnosis of Meningitis

Objective 1:

To list the important causative agents of meningitis.

TYPES OF MENINGITIS

 Acute Pyogenic Meningitis
 Aseptic Meningitis
 Chronic Meningitis

Tuberculous
 Fungal
 Syphillitic
 Protozoal
 Helminthe



Causative agents of acute pyogenic meningitis
• Neonates
– Escherichia coli
– Group B streptococci
– Listeria monocytogenes
– Streptococcus pneumoniae
• Children
– Neisseria meningitidis
– Streptococcus pneumoniae,
– Haemophilus influenzae
• Adults
– Streptococcus pneumoniae,
– Neisseria meningitidis
• Elderly
– Listeria species
Causative ...]]></description>
			<content:encoded><![CDATA[<h3><em>Presentation on Etiological factors and Laboratory Diagnosis of Meningitis</em></h3>
<p><a href="http://medchrome.com/wp-content/uploads/2010/08/Meningitis.jpg"><img class="aligncenter size-full wp-image-1665" title="Meningitis" src="http://medchrome.com/wp-content/uploads/2010/08/Meningitis.jpg" alt="Causative agents of meningitis" width="400" height="300" /></a></p>
<p><span style="color: #ff6600;"><em>Objective 1:</em></span></p>
<ul>
<li>To list the important causative agents of meningitis.</li>
</ul>
<p><em><span style="color: #ff6600;"><strong>TYPES OF MENINGITIS</strong></span></em></p>
<ul>
<li> Acute Pyogenic Meningitis</li>
<li> Aseptic Meningitis</li>
<li> Chronic Meningitis
<ul>
<li>Tuberculous</li>
<li> Fungal</li>
<li> Syphillitic</li>
<li> Protozoal</li>
<li> Helminthe</li>
</ul>
</li>
</ul>
<p><em><strong><span style="color: #ff6600;">Causative agents of acute pyogenic meningitis</span></strong></em></p>
<p>• <span style="color: #008000;">Neonates</span><br />
– Escherichia coli<br />
– Group B streptococci<br />
– Listeria monocytogenes<br />
– Streptococcus pneumoniae</p>
<p>• <span style="color: #008000;">Children</span><br />
– <a rel="follow" href="http://medchrome.com/basic-science/microbiology/microbiology-of-neisseria-meningitidis/" target="_blank">Neisseria meningitidis</a><br />
– Streptococcus pneumoniae,<br />
– Haemophilus influenzae</p>
<p>• <span style="color: #008000;">Adults</span><br />
– Streptococcus pneumoniae,<br />
– Neisseria meningitidis</p>
<p>• <span style="color: #008000;">Elderly</span><br />
– Listeria species</p>
<p><em><strong><span style="color: #ff6600;">Causative Agents of Aseptic meningitis</span></strong></em></p>
<p>•<span style="color: #008000;"> Common:</span><br />
- Enteroviruses<br />
- Herpes simplex virus 2 (HSV 2)<br />
- Arthropod borne viruses (Tickborne, West Nile, Murray Valley, Japanese B)<br />
- HIV (Human Immunodeficiency Virus)</p>
<p>• <span style="color: #008000;">Less common</span><br />
- Varicella zoster virus (VZV)<br />
- Epstein Barr virus (EBV)</p>
<p><strong><em><span style="color: #ff6600;">Causative Agents of Chronic Meningitis</span></em></strong></p>
<p><span style="color: #008000;">Tuberculous meningitis </span></p>
<ul>
<li>Mycobacterium tuberculosis</li>
</ul>
<p><span style="color: #008000;">Syphillitic meningits </span></p>
<ul>
<li>Treponema pallidum</li>
</ul>
<p><span style="color: #008000;">Fungal meningitis</span></p>
<p>• Cryptococcus neoformans (most common in HIV patients)<br />
• Candida albicans<br />
• Mucor species<br />
• Aspergillus fumigatus<br />
• Coccidioides immitis<br />
• Histoplasma capsulatum<br />
• Blastomyces dermatitidis</p>
<p><span style="color: #008000;">Protozoal </span></p>
<p>• Toxoplasma gondii<br />
• Trypanosoma<br />
• Acanthamoeba</p>
<p><span style="color: #008000;">Helminthes</span></p>
<p>• Taenia solium</p>
<p><em><span style="color: #ff6600;">Objective 2: </span></em></p>
<ul>
<li>To outline laboratory diagnosis of bacterial meningitis.</li>
</ul>
<p><em><strong><span style="color: #ff6600;">Specimens</span></strong></em></p>
<ul>
<li> CSF</li>
<li> Blood</li>
<li> Sample</li>
<li> Nasal swab</li>
<li> Peticheal lesions</li>
<li> Autopsy</li>
</ul>
<p><strong><em><span style="color: #ff6600;">A. Examination of CSF</span></em></strong></p>
<p><span style="color: #008000;">Macroscopy</span><br />
• CSF is cloudy under increased pressure and blood may be seen.</p>
<p><span style="color: #008000;">CSF is centrifuged and following methods are used:</span></p>
<ul>
<li> Microscopy</li>
<li> Culture</li>
</ul>
<p><em><span style="color: #ff6600;">Microscopy </span></em></p>
<p><span style="color: #008000;">Unstained preparations: </span>wet mounts</p>
<p><span style="color: #008000;">Stained smears:</span></p>
<ul>
<li> Common stains: Gram stain, Ziehl-Neelsen stain</li>
<li> Fluorescent dyes: Acridine orange, Auramine rhodamine</li>
</ul>
<div id="attachment_1666" class="wp-caption aligncenter" style="width: 460px"><a href="http://medchrome.com/wp-content/uploads/2010/08/Gram-and-ZN-stain.jpg"><img class="size-full wp-image-1666" title="Gram and ZN stain" src="http://medchrome.com/wp-content/uploads/2010/08/Gram-and-ZN-stain.jpg" alt="Gram and ZN stain Meningitis : Causative Agents and Lab diagnosis" width="450" height="151" /></a><p class="wp-caption-text">Gram stain (left) and ZN stain (right)</p></div>
<p><em><span style="color: #ff6600;">Culture</span></em></p>
<p><span style="color: #008000;">Culture Media</span></p>
<ul>
<li>Enriched solid media- blood agar, chocolate agar</li>
<li> Selective solid medium- MacConkey agar</li>
<li> Robertson Cooked meat broth (for anaerobes)</li>
</ul>
<p><span style="color: #008000;">Steps:</span></p>
<ul>
<li>CSF inoculated in culture media</li>
<li> incubation at 35-36°C under 5-10% CO2</li>
<li> Colonies appear after 18-24 hours, identified by morphology and biochemical reactions.</li>
</ul>
<p><em><strong><span style="color: #ff6600;">B. Blood culture</span></strong></em></p>
<ul>
<li> incubated for 4-7 days, with daily subcultures</li>
</ul>
<p><em><strong><span style="color: #ff6600;">C. Nasopharyngeal Swab</span></strong></em></p>
<p>• Useful for detection of carriers<br />
• Done without contamination with saliva</p>
<p><span style="color: #ff6600;"><em><strong>D. Petechial lesions</strong></em></span></p>
<p>Menigococci may be demonstrated by microscopy and culture</p>
<p><em><strong><span style="color: #ff6600;">E. Autopsy</span></strong></em></p>
<p>• Specimen from meninges, lateral ventricles, or surface of brain and spinal cord<br />
• Within 12 hours of death of patient<br />
• Smear or culture</p>
<p><em><strong><span style="color: #ff6600;">Biochemical tests</span></strong></em></p>
<p>• Catalase test<br />
• Oxidase test<br />
• Indole test<br />
• Urease test<br />
• Coagulase test<br />
• Citrate Utilization test<br />
• Triple sugar iron agar</p>
<p><strong><em><span style="color: #ff6600;">Agglutination test:</span></em></strong></p>
<ul>
<li>Direct slide agglutination test with specific antisera</li>
<li> Latex agglutination test</li>
<li>Immunoflourescence test</li>
<li> Other rapid identification methods</li>
<li> Molecular diagnosis – PCR test</li>
</ul>
<p><span style="color: #ff6600;"><em><strong>Various changes in Acute Pyogenic Meningitis:</strong></em></span></p>
<p><a href="http://medchrome.com/wp-content/uploads/2010/08/Normal-and-meningitis-comparison.jpg"><img class="aligncenter size-full wp-image-1667" title="Normal and meningitis comparison" src="http://medchrome.com/wp-content/uploads/2010/08/Normal-and-meningitis-comparison.jpg" alt="Normal and meningitis comparison Meningitis : Causative Agents and Lab diagnosis" width="400" height="231" /></a></p>
<p><em><span style="color: #ff6600;">References:</span></em></p>
<ul>
<li>Textbook of Microbiology</li>
<li>Diagnostic Microbiology</li>
</ul>
<p style="text-align: left;"><em><span style="color: #ff6600;">Prepared and Presented for Correlation Seminar in Kist Medical College by:</span></em></p>
<table style="background-color: grey;" border="1">
<tbody>
<tr>
<td>
<ul>
<li style="text-align: left;"><span style="color: #ffff00;">Sharmila Phelu (76)</span></li>
<li><span style="color: #ffff00;">Shradda Shrestha (77)</span></li>
<li><span style="color: #ffff00;">Shuvechha Pandey (78)</span></li>
<li><span style="color: #ffff00;">Srijana Shakya (79)</span></li>
<li style="text-align: left;"><span style="color: #ffff00;">Sulav Shrestha (80)</span></li>
<li><span style="color: #ffff00;">Surakshya Rayamajhi (81)</span></li>
<li><span style="color: #ffff00;">Surendra Pariyar (82)</span></li>
<li><span style="color: #ffff00;">Sushil Dulal (83)</span></li>
<li><span style="color: #ffff00;">Sushmita Sharma (84)</span></li>
<li><span style="color: #ffff00;">Tulsi Ram Shrestha (85)</span></li>
<li><span style="color: #ffff00;">Uday Chandra Prakash (86)</span></li>
<li><span style="color: #ffff00;">Ujjwol Giri (87)</span></li>
<li><span style="color: #ffff00;">Ujwol Karmacharya (88)</span></li>
</ul>
</td>
</tr>
</tbody>
</table><img src="http://medchrome.com/?ak_action=api_record_view&id=1664&type=feed" alt=" Meningitis : Causative Agents and Lab diagnosis"  title="Meningitis : Causative Agents and Lab diagnosis" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/basic-science/meningitis-causative-agents-and-lab-diagnosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medical School Pathology for Self Learners</title>
		<link>http://medchrome.com/basic-science/pathology/medical-school-pathology-for-self-learners/</link>
		<comments>http://medchrome.com/basic-science/pathology/medical-school-pathology-for-self-learners/#comments</comments>
		<pubDate>Sat, 17 Jul 2010 12:50:18 +0000</pubDate>
		<dc:creator>Sulav Shrestha</dc:creator>
				<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[Student Life]]></category>
		<category><![CDATA[Medical videos]]></category>
		<category><![CDATA[online lab]]></category>
		<category><![CDATA[online learning]]></category>
		<category><![CDATA[online resouces]]></category>
		<category><![CDATA[powerpoint slides]]></category>
		<category><![CDATA[SDL]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=1493</guid>
		<description><![CDATA[Pathology is an interesting subject but it is as difficult as any other subjects in medical science like anatomy, physiology, pharmacology, etc. We all are made differently and we all have different way of learning or studying. The method that I use to study may or may not be suitable to you. Lectures, books, pictures and slides are the common ...]]></description>
			<content:encoded><![CDATA[<div id="attachment_1499" class="wp-caption aligncenter" style="width: 469px"><a href="http://medchrome.com/wp-content/uploads/2010/07/online-learning.jpg"><img class="size-full wp-image-1499" title="online learning" src="http://medchrome.com/wp-content/uploads/2010/07/online-learning.jpg" alt="Online Resources" width="459" height="317" /></a><p class="wp-caption-text">Studying Online</p></div>
<p>Pathology is an interesting subject but it is as difficult as any other subjects in medical science like anatomy, physiology, pharmacology, etc. We all are made differently and we all have different way of learning or studying. The method that I use to study may or may not be suitable to you. Lectures, books, pictures and slides are the common sources of learning. Using online resources to learn may be very helpful to many of us.</p>
<h3><em><span style="font-weight: normal;"><span style="color: #3366ff;">It is a vast subject and its knowledge is always expanding. So, it is more important that the pathology learnt in the undergraduate curriculum (like MBBS Basic Science) is basic and relevant, emphasizing the understanding of mechanisms and principles rather than detailed facts. As students continue their medical education into PG trainee years, more detailed systemic pathology will become more relevant and more appropriately learnt at that time.</span></span></em></h3>
<div><strong>Review of Medical School Pathology</strong></div>
<p>Site home: <a href="http://medicalschoolpathology.com" rel="nofollow" target="_blank">http://medicalschoolpathology.com</a></p>
<p>Medical School Pathology is a resourceful medical website designed to assist self learner medical students for learning pathology. It provides online access to lecture notes and videos of all 29 chapters based on Robbin&#8217;s Pathology. Besides, it also provides medics with online laboratory for learning histopathology. This site probably won&#8217;t be useful to lay person because the description are mostly medical and includes medical jargons.</p>
<p><span style="color: #ff6600;"><em>Chapters</em></span></p>
<p><span style="color: #3366ff;">GENERAL PATHOLOGY</span></p>
<p>1.	Cellular Adaptations, Cell Injury, and Cell Death<br />
2.	Acute and Chronic Inflammation<br />
3.	Tissue Repair: Cellular Growth, Fibrosis, and Wound Healing<br />
4.	Hemodynamic Disorders, Thrombosis, and Shock</p>
<div id="attachment_1437" class="wp-caption alignright" style="width: 236px"><a href="http://medchrome.com/wp-content/uploads/2010/07/robbins-pathology.jpg"><img class="size-medium wp-image-1437" title="robbins pathology" src="http://medchrome.com/wp-content/uploads/2010/07/robbins-pathology-226x300.jpg" alt="Pathological Basis of Disease - Robbins and Cotran" width="226" height="300" /></a><p class="wp-caption-text">Textbook for pathology</p></div>
<p>5.	Genetic Disorders<br />
6.	Diseases of Immunity<br />
7.	Neoplasia<br />
8.	Infectious Diseases<br />
9.	Environmental and Nutritional Pathology<br />
10.	Diseases of Infancy and Childhood</p>
<p><span style="color: #3366ff;">DISEASES OF ORGAN SYSTEMS</span></p>
<p>11.	Blood Vessels<br />
12.	The Heart<br />
13.	Red Cells and Bleeding Disorders<br />
14.	White Cells, Lymph Nodes, Spleen, and Thymus<br />
15.	The Lung<br />
16.	Head and Neck<br />
17.	The Gastrointestinal Tract<br />
18.	The Liver and Biliary Tract<br />
19.	The Pancreas<br />
20.	The Kidney<br />
21.	The Lower Urinary Tract and the Male Genital Tract<br />
22.	The Female Genital Tract<br />
23.	The Breast<br />
24.	The Endocrine System<br />
25.	The Skin<br />
26.	Bones, Joints, and Soft Tissue Tumors<br />
27.	Peripheral Nerve and Skeletal Muscle<br />
28.	The Central Nervous System<br />
29.	The Eye</p>
<h3><span style="color: #ff6600;">Online Resources For Self-Learning</span></h3>
<p><span style="color: #008000;"><em>Download</em></span> <a href="http://www.medicalschoolpathology.com/PPTs.htm">Lecture notes in Powerpoint</a><br />
<em><span style="color: #008000;">Watch and Download </span></em><a href="http://www.medicalschoolpathology.com/PathILectures/">Lecture videos of General Pathology</a><br />
<em><span style="color: #008000;">Watch and Download </span></em><a href="http://www.medicalschoolpathology.com/PathILectures/">Lecture videos of Systemic Pathology</a><br />
<span style="color: #008000;"><em>Watch and Download</em></span> <a href="http://www.medicalschoolpathology.com/HistopathologyWMVs/">Histopathology Videos</a><br />
<span style="color: #008000;"><em> Online Access to </em></span><a href="http://www.medicalschoolpathology.com/RockLab.htm"><em>R</em>ock Lab for Independent Study</a><br />
<a href="http://www.medicalschoolpathology.com/ShotgunHistology.htm">Shotgun Histology</a></p><img src="http://medchrome.com/?ak_action=api_record_view&id=1493&type=feed" alt=" Medical School Pathology for Self Learners"  title="Medical School Pathology for Self Learners" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/basic-science/pathology/medical-school-pathology-for-self-learners/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>DMARDS in the treatment of rheumatoid arthritis</title>
		<link>http://medchrome.com/basic-science/pharmacology/dmards-in-the-treatment-of-rheumatoid-arthritis/</link>
		<comments>http://medchrome.com/basic-science/pharmacology/dmards-in-the-treatment-of-rheumatoid-arthritis/#comments</comments>
		<pubDate>Fri, 02 Jul 2010 15:31:44 +0000</pubDate>
		<dc:creator>Jms S Mhn</dc:creator>
				<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[anakinra]]></category>
		<category><![CDATA[auranofin]]></category>
		<category><![CDATA[d-penicillamine]]></category>
		<category><![CDATA[DMARD]]></category>
		<category><![CDATA[etanercept]]></category>
		<category><![CDATA[immunosupressants]]></category>
		<category><![CDATA[infliximab]]></category>
		<category><![CDATA[leflunomide]]></category>
		<category><![CDATA[prednisolone]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Rheumatoid arthritis]]></category>
		<category><![CDATA[rheumatoid factor]]></category>
		<category><![CDATA[sulfasalazine]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=1380</guid>
		<description><![CDATA[Presentation on Present status of DMARDS in the treatment of RA
 
Objective

To highlight the present status of disease modifying anti-rheumatic drugs (DMARDs) in  the treatment of rheumatoid arthritis

Introduction

DMARDs (disease modifying antirheumatic drugs) are drugs which can suppress the rheumatoid process and bring about a remission, but do not have nonspecific anti-inflammatory or analgesic action.

Classification of Anti-rheumatic drugs
A. DMARDs:

Immunosuppressants: Methotrexate, ...]]></description>
			<content:encoded><![CDATA[<h1 style="text-align: center;"><span style="font-weight: normal;"><em><span style="color: #ff6600;">Presentation on Present status of DMARDS in the treatment of RA</span></em></span></h1>
<p style="text-align: center;"><span style="color: #ff6600;"><em> </em></span></p>
<div id="attachment_1381" class="wp-caption aligncenter" style="width: 238px"><a href="http://medchrome.com/wp-content/uploads/2010/07/RA-treatment.jpg"><img class="size-medium wp-image-1381" title="RA treatment" src="http://medchrome.com/wp-content/uploads/2010/07/RA-treatment-228x300.jpg" alt="RA treatment 228x300 DMARDS in the treatment of rheumatoid arthritis" width="228" height="300" /></a><p class="wp-caption-text">Click on the picture to enlarge</p></div>
<h3><span style="font-weight: normal;"><span style="color: #008000;">Objective</span></span></h3>
<ul>
<li>To highlight the present status of <span style="color: #3366ff;">disease modifying anti-rheumatic drugs (DMARDs)</span> in  the treatment of rheumatoid arthritis</li>
</ul>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Introduction</span></span></h3>
<ul>
<li>DMARDs (disease modifying antirheumatic drugs) are drugs which can suppress the rheumatoid process and bring about a remission, but do not have nonspecific anti-inflammatory or analgesic action.</li>
</ul>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Classification of Anti-rheumatic drugs</span></span></h3>
<p><span style="color: #3366ff;">A. DMARDs:</span></p>
<ul>
<li>Immunosuppressants: Methotrexate, Cyclosporine, Azathioprine</li>
<li>Sulfasalazine</li>
<li>Chloroquine or hydroxychloroquine</li>
<li>Leflunomide</li>
<li>Gold salts</li>
<li>d-Penicillamine</li>
</ul>
<p><span style="color: #3366ff;">B. Biological response modifiers(BRMs):</span></p>
<ul>
<li>TNF-α inhibitors: Etanercept, Infliximab</li>
<li>IL-1 antagonist: Anakinra</li>
</ul>
<p><span style="color: #3366ff;">C. Adjuvant drugs</span></p>
<ul>
<li>Corticosteroids: Prednisolone</li>
</ul>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Immunosuppressants</span></span></h3>
<p><span style="color: #008000;">Methotrexate:</span></p>
<ul>
<li><span style="color: #3366ff;">First choice</span> and standard drug for rheumatoid arthritis.</li>
<li>Acts by inhibiting an enzyme dihydrofolate reductase</li>
<li>Also inhibits other enzyme involve in protein synthesis as well as anti-inflammatory and cytokines modulating effect.</li>
<li>Initially low dose(7.5-15 mg/week)</li>
<li><span style="color: #3366ff;">Best tolerated</span> among other DMARDs</li>
</ul>
<p><span style="color: #3366ff;">Adverse drug effects</span></p>
<ol>
<li>Nausea and mouth ulcer</li>
<li>Pancytopenia (low blood cells)</li>
<li>Liver cirrhosis</li>
<li>Acute pneumonitis</li>
</ol>
<p><span style="color: #3366ff;">Contraindications</span><br />
• Pregnancy<br />
• Lactating mother<br />
• Liver disease<br />
• Leucopenia<br />
• Peptic ulcer</p>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Sulfasalazine</span></span></h3>
<ul>
<li>It is a compound of sulfapyridine and 5-amino salicyclic acid (5-ASA)</li>
<li>Useful in both RA and ulcerative colitis</li>
<li>Much more safer than gold salts</li>
<li><span style="color: #3366ff;">Second line drugs</span> for milder cases</li>
<li>Mode of action is unknown</li>
</ul>
<p><span style="color: #3366ff;">Adverse drug effects:</span></p>
<ol>
<li>Neutropenia, hemolytic anemia</li>
<li>Thrombocytopenia</li>
</ol>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Gold Salts</span></span></h3>
<ul>
<li>Water soluble gold preparation like sodium aurothiomalate</li>
<li>Gets deposited in the synovial macrophages in actively inflammed joints and inhibits their function.</li>
</ul>
<p><span style="color: #3366ff;">Adverse drug effects:</span></p>
<ul>
<li>Dermatitis, nephropathy, bone marrow depression and liver damage.</li>
</ul>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Etanercept</span></span></h3>
<ul>
<li>It is a recombinant fusion protein of TNF-receptor and Fc portion of human IgG</li>
<li>Reserved for the patients who have failed to respond to adequate trials of atleast two DMARDs</li>
</ul>
<p><span style="color: #3366ff;">Adverse drug reaction:</span></p>
<ol>
<li>Pain, redness, itching, swelling at the infection site</li>
<li>Chest infection may be increasedd-Penicillamine</li>
<li>Splits the rheumatoid factor and also selectively reduces the serum levels of calcium immunoglobin</li>
<li>Adverse drug reactions incidences are high so not commonly used</li>
</ol>
<p>Gold salts and d-penicillamine should not be combined for the treatment of RA (because of severe ADRs). <span style="color: #008000;">Gold salts and d-penicillamine are not used in the present context because of severe adverse reactions i.e.</span></p>
<ul>
<li>Bone marrow depression</li>
<li>Kidney and liver damage</li>
<li>Ulceration</li>
</ul>
<p><span style="color: #ff6600;"><span style="font-weight: normal;"><em>Presented by Students of KistMCTH 1st year students</em></span></span></p>
<p><em></p>
<ol>
<li>Hemu Chaurasia(Roll no-36)</li>
<li>Jemesh Singh Maharjan (Roll no-37)</li>
<li>Jeni Thapa(Roll no-38)</li>
<li>Keshav KC (Roll no-39)</li>
<li>Manisha Bohara (Roll no-40)</li>
<li>Manisha Dhakal (Roll no-41)</li>
<li><strong><span style="font-weight: normal;"><em>Manisha Maharjan (Roll no-42)</em></span><em> </em></strong></li>
</ol>
<p></em></p>
<h3><span style="color: #008000;"><span style="font-weight: normal;">Reference</span></span></h3>
<ol>
<li>Text book of Pharmacology- K D Tripathi</li>
<li>Text book of Pharmacology- Bennett and Brown</li>
</ol><img src="http://medchrome.com/?ak_action=api_record_view&id=1380&type=feed" alt=" DMARDS in the treatment of rheumatoid arthritis"  title="DMARDS in the treatment of rheumatoid arthritis" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/basic-science/pharmacology/dmards-in-the-treatment-of-rheumatoid-arthritis/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
		</item>
		<item>
		<title>Rheumatoid Factor and Its Daignostic Importance</title>
		<link>http://medchrome.com/basic-science/microbiology/rheumatoid-factor-and-its-daignostic-importance/</link>
		<comments>http://medchrome.com/basic-science/microbiology/rheumatoid-factor-and-its-daignostic-importance/#comments</comments>
		<pubDate>Sat, 19 Jun 2010 03:47:27 +0000</pubDate>
		<dc:creator>Sulav Shrestha</dc:creator>
				<category><![CDATA[Microbiology]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[ACPAs]]></category>
		<category><![CDATA[ANA]]></category>
		<category><![CDATA[anti-citrullinated protein antibodies]]></category>
		<category><![CDATA[CBC]]></category>
		<category><![CDATA[CRP]]></category>
		<category><![CDATA[ESR]]></category>
		<category><![CDATA[Joints]]></category>
		<category><![CDATA[ppt]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Rheumatoid arthritis]]></category>
		<category><![CDATA[rheumatoid factor]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=1266</guid>
		<description><![CDATA[A presentaion on rheumatoid factor and its significance in diagnosis of rheumatoid arthritis by students of Kist Medical College

Objectives

To define Rheumatoid Factor .
To explain briefly its significance in the diagnosis of rheumatoid arthritis.

Rheumatoid factor

Rheumatoid factor (RF) is an autoantibody that is directed against organism’s own tissues, most relevant in rheumatoid arthritis.
An antibody against the Fc portion of IgG, which is ...]]></description>
			<content:encoded><![CDATA[<h2 style="text-align: center;"><span style="font-weight: normal;"><em><span style="color: #800000;">A presentaion on rheumatoid factor and its significance in diagnosis of <a href="http://medchrome.com/featured/rheumatoid-arthritis-dr-binit-vaidya/" target="_blank">rheumatoid arthritis</a> by students of Kist Medical College</span></em></span></h2>
<p style="text-align: center;"><img class="aligncenter" src="http://medchrome.com/wp-content/uploads/2009/12/rheum03-300x244.jpg" alt="rheum03 300x244 Rheumatoid Factor and Its Daignostic Importance"  title="Rheumatoid Factor and Its Daignostic Importance" /></p>
<h3><span style="color: #ff6600;"><span style="font-weight: normal;">Objectives</span></span></h3>
<ul>
<li><span style="color: #008000;">To define Rheumatoid Factor .</span></li>
<li><span style="color: #008000;">To explain briefly its significance in the diagnosis of <a href="http://medchrome.com/featured/rheumatoid-arthritis-dr-binit-vaidya/" target="_blank">rheumatoid arthritis</a>.</span></li>
</ul>
<h3><span style="font-weight: normal;"><span style="color: #ff6600;">Rheumatoid factor</span></span></h3>
<ul>
<li><span style="color: #008000;">Rheumatoid factor (RF) is an autoantibody that is directed against organism’s own tissues, most relevant in rheumatoid arthritis.</span></li>
<li><span style="color: #008000;">An antibody against the Fc portion of IgG, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.</span></li>
</ul>
<h3><span style="font-size: 15px; color: #ff6600;"><span style="font-weight: normal;">Diagnosis of RA</span></span></h3>
<ul>
<li><span style="color: #008000;">Diagnosis is based on clinical test, signs and symptoms and imaging technique.</span></li>
<li><span style="color: #008000;">The test for RF may be ordered when a person has signs of RA.</span></li>
<li><span style="color: #008000;">Symptoms : pain, warmth, swelling, and morning stiffness in the joints, nodules under the skin</span></li>
<li><span style="color: #008000;">X-rays of swollen joint capsules</span></li>
<li><span style="color: #008000;">An RF test may be repeated when the first test is negative and symptoms persist.</span></li>
</ul>
<p><span style="color: #008000;"><span style="color: #ff6600;"> </span></span></p>
<h3><span style="color: #008000;"><span style="color: #ff6600;"><span style="font-weight: normal;">Significant associations</span></span></span></h3>
<ul>
<li><span style="color: #008000;">Rheumatoid disease including Rheumatoid Arthritis .</span></li>
<li><span style="color: #008000;">Higher the level of RF, the worse the joint destruction and greater the chance of systemic involvement.</span></li>
</ul>
<p><span><span style="color: #ff6600;">Associations</span></span><br />
<span style="color: #008000;">Rheumatoid arthritis (60-70%)</span><br />
<span style="color: #008000;">Sjögrens syndrome (≤100 %)</span><br />
<span style="color: #008000;">Felty&#8217;s syndrome (≤100 %)</span><br />
<span style="color: #008000;">Systemic sclerosis (30%)</span><br />
<span style="color: #008000;">Infective endocarditis (≤ 50%)</span><br />
<span style="color: #008000;">Systemic lupus erythematous (≤ 40%)</span><br />
<span style="color: #008000;">Infectious mononucleosis</span><br />
<span style="color: #008000;">Hepatitis</span><br />
<span style="color: #008000;">TB</span><br />
<span style="color: #008000;">Cancer</span></p>
<ul></ul>
<h3><span style="color: #ff6600;"><span style="font-weight: normal;">RF Test</span></span></h3>
<ul>
<li><span style="color: #008000;">RF is commonly used as a blood test for the diagnosis of rheumatoid arthritis.</span></li>
<li><span style="color: #008000;">A negative RF is seronegative , in about 15% of patients.</span></li>
<li><span style="color: #008000;">During the first year of RA, RF is more likely to be negative but some individuals convert to seropositive later.</span></li>
</ul>
<h3><span style="color: #ff6600;"><span style="font-weight: normal;">CRITERIA</span></span></h3>
<ul>
<li><span style="color: #008000;">High levels of rheumatoid factor</span></li>
<li><span style="color: #008000;">Generally above 20 IU/mL</span></li>
<li><span style="color: #008000;">Upto dilution level 1:40 (of rheumatoid factor)</span></li>
<li><span style="color: #008000;">In 80% cases</span></li>
</ul>
<h3><span style="color: #ff6600;"><span style="font-weight: normal;">Other Serological Tests</span></span></h3>
<p><span style="color: #008000;"></p>
<ul>
<li>New test for the presence of anti-citrullinated protein antibodies (ACPAs).</li>
<li><span><span style="color: #008000;">ANA (antinuclear antibody)</span></span></li>
<li><span><span style="color: #008000;">CRP (C-reactive protein)</span></span></li>
<li><span><span style="color: #008000;">ESR (erythrocyte sedimentation rate)</span></span></li>
<li><span><span style="color: #008000;">CBC (Complete Blood Count)</span></span></li>
</ul>
<p></span></p>
<ul></ul>
<h3><span style="color: #ff6600;"><span style="font-weight: normal;">SUMMARY</span></span></h3>
<ul>
<li><span style="color: #008000;">Rheumatoid factor   (RF) an antibody ( IgM )</span></li>
<li><span style="color: #008000;">It is used for the diagnosis of Rheumatoid arthritis</span></li>
<li><span style="color: #008000;">But it is not the confirmational test because it is observed in other related and unrelated diseases</span></li>
</ul>
<div id="__ss_4540847" style="width: 425px;"><strong><a title="Rheumatoid Factor and Its Diagnositc Significance" href="http://www.slideshare.net/sulavmetal/rheumatoid-factor-and-its-diagnositc-significance">Rheumatoid Factor and Its Diagnositc Significance</a></strong><object id="__sse4540847" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="425" height="355" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="allowFullScreen" value="true" /><param name="allowScriptAccess" value="always" /><param name="src" value="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=ramicrobiology-100618221638-phpapp02&amp;stripped_title=rheumatoid-factor-and-its-diagnositc-significance" /><param name="name" value="__sse4540847" /><param name="allowfullscreen" value="true" /><embed id="__sse4540847" type="application/x-shockwave-flash" width="425" height="355" src="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=ramicrobiology-100618221638-phpapp02&amp;stripped_title=rheumatoid-factor-and-its-diagnositc-significance" name="__sse4540847" allowscriptaccess="always" allowfullscreen="true"></embed></object>View more <a href="http://www.slideshare.net/">presentations</a> from <a href="http://www.slideshare.net/sulavmetal">Sulav Shrestha</a>.</p>
</div>
<h3><span style="font-weight: normal;"><em><span style="color: #ff6600;">Prepared by:</span><br />
Samjhana Sharma (73)<br />
Sashi Kumar Yadav (74)<br />
Sat Prasad Nepal (75)<br />
Sharmila Phellu (76)<br />
Shraddha Shrestha (77)<br />
Shuvechha Pandey (78)<br />
Srijana Shakya (79)<br />
Sulabh Shrestha (80)<br />
Surakshya Rayamajhi (81)<br />
Surendra Pariyar (82)<br />
Sushil Dulal (83)<br />
Sushmita Bajagain (84)<br />
Tulsi Ram Shrestha (85)<br />
Uday Chandra Prakash (86)</em></span></h3><img src="http://medchrome.com/?ak_action=api_record_view&id=1266&type=feed" alt=" Rheumatoid Factor and Its Daignostic Importance"  title="Rheumatoid Factor and Its Daignostic Importance" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/basic-science/microbiology/rheumatoid-factor-and-its-daignostic-importance/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Hepatocellular Carcinoma or Liver Cancer</title>
		<link>http://medchrome.com/downloads/presentations/hepatocellular-carcinoma-or-liver-cancer/</link>
		<comments>http://medchrome.com/downloads/presentations/hepatocellular-carcinoma-or-liver-cancer/#comments</comments>
		<pubDate>Sun, 30 May 2010 15:31:08 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
				<category><![CDATA[Hepato-biliary]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[chemoembolization]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[liver cancer]]></category>
		<category><![CDATA[liver tumor]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=1083</guid>
		<description><![CDATA[Hepatocellular Carcinoma Or Liver Cancer: Causes, Clinal Features, Diagnosis and Management
• Hepatocellular carcinoma (HCC) is a primary malignancy of the hepatocyte, generally leading to death within 6-20 months. 
• Hepatocellular carcinoma frequently arises in the setting of cirrhosis, appearing 20-30 years following the initial insult to the liver.
• 25% of patients have no history or risk factors for the development ...]]></description>
			<content:encoded><![CDATA[<p style="text-align: justify;"><span style="color: #0000ff;"><strong><span style="color: #ff6600;">Hepatocellular Carcinoma Or Liver Cancer: Causes, Clinal Features, Diagnosis and Management</span></strong></p>
<p>• Hepatocellular carcinoma (HCC) is a primary malignancy of the hepatocyte, generally leading to death within 6-20 months.</span> <span style="color: #0000ff;"><br />
• Hepatocellular carcinoma frequently arises in the setting of cirrhosis, appearing 20-30 years following the initial insult to the liver.<br />
• 25% of patients have no history or risk factors for the development of cirrhosis.<br />
• currently one of the most common worldwide causes of cancer death </span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"></p>
<div id="attachment_1084" class="wp-caption aligncenter" style="width: 310px"><a href="http://medchrome.com/wp-content/uploads/2010/05/Liver_Tumor.jpg"><img class="size-medium wp-image-1084" title="Liver_Tumor" src="http://medchrome.com/wp-content/uploads/2010/05/Liver_Tumor-300x225.jpg" alt="Liver Tumor 300x225 Hepatocellular Carcinoma or Liver Cancer" width="300" height="225" /></a><p class="wp-caption-text">Massive Liver tumor</p></div>
<p></span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Epidemiology</span>: worldwide (China, sub-Saharan Africa, Japan)</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Pathophysiology</span><br />
• Tumors are multifocal within the liver 75% of the time. Late in the disease, metastases may develop in the lung, portal vein, periportal nodes, bone, or brain.<br />
<span style="color: #ff6600;"> </span></span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Mortality/Morbidity</span><br />
</span></p>
<ul style="text-align: justify;">
<li><span style="color: #0000ff;"> Cure, usually through surgery, is possible in fewer than 5% of all patients.</span></li>
<li><span style="color: #0000ff;"> Median survival from time of diagnosis is generally 6 months.</span></li>
<li><span style="color: #0000ff;"> portal vein occlusion, which occurs commonly,portends an even shorter survival.</span></li>
<li><span style="color: #0000ff;">Complications from hepatocellular carcinoma are those of hepatic failure; death occurs from cachexia, variceal bleeding, or (rarely) tumor rupture and bleeding into the peritoneum</span></li>
</ul>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Race •</span> Hepatocellular carcinoma is most commonly found among Asian persons, due to childhood infections with hepatitis B.</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;"><br />
Sex</span><br />
• Hepatocellular carcinoma occurs more commonly in men than in women</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Age</span><br />
• Hepatocellular carcinoma is rarely diagnosed in persons younger than 40  years.<br />
• In Africa and Asia, age at diagnosis is substantially younger, occurring in the fourth and fifth decades of life, respectively.</span></p>
<p style="text-align: justify;">
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;"><strong>Etiology</strong></span><br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">1. Cirrhosis</span><br />
About 80% of patients with newly diagnosed hepatocellular carcinoma have preexisting  cirrhosis attributed to alcohol, hepatitis C infection, and hepatitis B infection.<br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">2.Hepatitis B virus</span><br />
• Global incidence of chronic HBV infection is estimated to be 350 million persons; chronic HBV infection is the most common cause of  hepatocellular carcinoma worldwide.<br />
• Chronic infection in the setting of cirrhosis increases the risk of hepatocellular carcinoma 1000-fold.</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"> <span style="color: #ff6600;">3.Hepatitis C virus<br />
</span> • HCV is a global pandemic affecting 170 million persons. HCV infection results in a higher rate of chronic infection compared to HBV infection (approximately 80% of<br />
infected subjects).<br />
• It has become the most common cause of hepatocellular carcinoma in Japan and Europe. About 30% progress to cirrhosis, and in these, about 1-2% per year develop<br />
hepatocellular carcinoma.<br />
• Co-infection with HBV further increases the risk</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">4. Hemochromatosis:.</span><br />
<span style="color: #ff6600;">5. Aflatoxin:</span> This hepatic carcinogen is a byproduct of fungal contamination of foodstuffs in sub-Saharan Africa and East and Southeast Asia. It causes DNA damage and mutations of the p53<br />
gene.<br />
<em><span style="color: #ff6600;">Rare associations:</span></em><br />
1. Primary Biliary Cirrhosis<br />
2. Androgenic steroids,<br />
3. Primary Sclerosing Cholangitis<br />
4. 1-antitrypsin deficiency<br />
5. Thorotrast radioactive contrast<br />
6. Oral contraceptives<br />
7. Porphyria cutanea tarda.<br />
8. Obesity and diabetes  have been implicated as risk factors for hepatocellular carcinoma ( related to NASH and Non Alcoholic Fatty Liver)</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><strong>Clinical History</strong><br />
• Patients generally present with symptoms of advancing cirrhosis.<br />
• Pruritis<br />
• Jaundice<br />
• Splenomegaly<br />
• Variceal bleeding<br />
• Cachexia<br />
• Increasing abdominal girth (portal vein occlusion by thrombus with rapid development of ascites)<br />
• Hepatic Encephalopathy<br />
• Right upper quadrant pain (uncommon)Physical<br />
• Jaundice<br />
• Ascites<br />
• Hepatomegaly<br />
• Alcoholic stigmata (Dupuytren contracture, spider angiomata)<br />
• Asterixis<br />
• Pedal edema<br />
• Periumbilical collateral veins<br />
• Enlarged hemorrhoidal veins</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><strong><span style="color: #ff6600;">Differential Diagnoses</span></strong><br />
A. Cholangiocarcinoma<br />
B. Cirrhosis<br />
C. Hepatocellular Adenoma<br />
Other Problems to Be Considered<br />
1. Dysplastic nodules in cirrhosis<br />
2. Fibrous nodular hyperplasia<br />
3. Metastatic disease<br />
4. Primary hepatic lymphomaDiagnosis<br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><strong><span style="color: #ff6600;">Laboratory Studies</span></strong><br />
• Expect total bilirubin, aspartate aminotransferase (AST), alkaline phosphatase, albumin, and prothrombin time to show results consistent with cirrhosis.<br />
• Alpha-fetoprotein (AFP) is elevated in 75% of cases.<br />
• The level of elevation correlates inversely with prognosis.<br />
• An elevation of greater than 400 ng/mL predicts for hepatocellular carcinoma with specificity greater than 95%.</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;">• Alpha-fetoprotein (AFP) is inadequate for screening purposes because of the high rate of false positives in active hepatitis; it only begins to rise when vascular invasion occurs</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Imaging Studies</span><br />
</span></p>
<ul style="text-align: justify;">
<li><span style="color: #0000ff;"> Ultrasonography</span></li>
<li><span style="color: #0000ff;">An advantage is that Doppler imaging can be performed at the same time to determine the patency of the portal vein.</span></li>
<li><span style="color: #0000ff;"> CT scanning   -Triphasic technique (ie, without contrast, then with early [arterial] and late [portal] imaging).CT scanning has the added benefit of detecting extrahepatic disease, especially lymphadenopathy.</span></li>
<li><span style="color: #0000ff;">MRI-detect smaller lesions and can also be used to determine flow in the portal vein. The overall sensitivity of MRI is thought to be similar to that of triphasic CT scanning.</span></li>
<li><span style="color: #0000ff;">Angiography-Shows characteristic tumor blush in hepatocellular carcinoma</span></li>
<li><span style="color: #0000ff;">Chest radiography may demonstrate pulmonary metastases</span></li>
<li><span style="color: #0000ff;"> Bone scanning and head CT scanning are of low yield in the absence of specific symptoms.</span></li>
<li><span style="color: #0000ff;">PET scan: Under experiment</span></li>
<li><span style="color: #0000ff;">Biopsy-Frequently necessary for diagnosis.Core biopsy is favored over fine needle biopsy since larger amounts of tissue, often with normal surrounding parenchyma, can be obtained.</span></li>
</ul>
<p style="text-align: justify;"><span style="color: #0000ff;"><em><span style="color: #ff6600;"> Biopsy</span></em> may be omitted in a clinical setting of a growing mass in a cirrhotic liver (&gt;2 cm) noted on 2 coincident imaging techniques with at least one imaging showing contrast enhancement.<br />
Likewise, a growing mass in a cirrhotic liver on one imaging modality with an associated AFP level greater than 500-1000 ng/mL is clinically diagnostic of hepatocellular carcinoma .  Biopsy is generally obtained percutaneously under ultrasonographic or CT guidance.<br />
Using laparoscopic guidance may make obtaining a percutaneous biopsy easier.  Obtaining a biopsy may be unnecessary in patients who will undergo resection regardless of diagnosis.</span></p>
<p style="text-align: justify;"><em><strong><span style="color: #ff6600;">• One system is the CLIP (Cancer of the Liver Italian Program) scoring system, which assigns a cumulative prognostic score ranging from 0-6 based upon</span></strong></em></p>
<p style="text-align: justify;"><span style="color: #0000ff;">1. Child-Pugh stage,<br />
2. tumor morphology,<br />
3. alpha-fetoprotein level,<br />
4. and portal vein thrombosis,<br />
5. can predict median survivalTNM staging criteria for hepatocellular carcinoma</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><br />
• T1 &#8211; Solitary tumor without vascular invasion<br />
• T2 &#8211; Solitary tumor with vascular invasion or multiple tumors none more than 5 cm<br />
• T3 &#8211; Multiple tumors more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)<br />
• T4 &#8211; Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum<br />
• N0 &#8211; Indicates no nodal involvement<br />
• N1 &#8211; Indicates regional nodal involvement<br />
• M0 &#8211; Indicates no distant metastasis<br />
• M1 &#8211; Indicates metastasis presence beyond the liverStage grouping<br />
• Stage I = T1 + N0 + M0<br />
• Stage II = T2 + N0 + M0<br />
• Stage IIIA = T3 + N0 + M0<br />
• Stage IIIB = T4 + N0 + M0<br />
• Stage IIIC = TX + N1 + M0<br />
• Stage IVB = TX + NX + M1CLIP scoring system: Score of 0-2 is assigned for each of the 4 features listed below; cumulative score ranging from 0-6 is the CLIP score.<br />
<span style="color: #ff6600;"> </span></span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Child-Pugh stage</span> Stage A = 0   Stage B = 1   Stage C = 2 </span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Tumor morphology</span><br />
Uninodular and extension less than 50% = 0<br />
Multinodular and extension less than 50% = 1<br />
Massive and extension greater than 50% = 2<br />
<span style="color: #ff6600;">Alpha-fetoprotein</span> Less than 400 = 0,  Greater than 400 = 1<br />
<span style="color: #ff6600;"> Portal vein thrombosis </span> Absent = 0  Present = 1<br />
</span></p>
<p style="text-align: justify;"><span style="color: #ff6600;">:Estimated  survival based on CLIP score</span><br />
<span style="color: #0000ff;"> • score of 0 – about 31 months;<br />
• score of 1- about 27 months;<br />
• score of 2- about 13 months;<br />
• score of 3- 8 months;<br />
• scores 4-6-approximately 2 months.Medical Care<br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;"><strong>Treatment:</strong></span><br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"> 1.Available treatment options depend on the size, number, and location of tumors; presence or absence of cirrhosis; operative risk based on extent of cirrhosis and comorbid diseases; overall performance status; patency of portal vein; and presence of metastatic disease.<br />
2.Before instituting definitive therapy<br />
• treat the complications of cirrhosis with diuretics,<br />
• paracentesis for ascites, l<br />
• actulose for encephalopathy,<br />
• ursodiol for pruritus,<br />
• sclerosis or banding for variceal bleeding, and<br />
• antibiotics for spontaneous bacterial peritonitis.<br />
• Surgical resection and liver transplantation are the only chances of cure but have limited applicability. Other local therapies are chemoembolization, ethanol ablation, radiofrequency ablation, cryoablation, and radiotherapy. Patients whose disease is downstaged following chemoembolization may be eligible for transplantation. Systemic treatment with chemotherapy may be used for  advanced disease.</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">Systemic chemotherapy</span><br />
The most active single agent drugs tested have been<br />
• doxorubicin,<br />
• cisplatin, and<br />
• fluorouracil.<br />
• Response rates are about 10%, and treatment shows no clear impact on overall survival.<br />
• More recently, gemcitabine and capecitabine have been evaluated in clinical trialscisplatin-based combination regimens, such as gemcitabine and oxaliplatin, have shown improved response rates around 20%,<br />
</span></p>
<p style="text-align: justify;"><span style="color: #ff6600;">Chemoimmunotherapy uses a combination of chemotherapy and immunomodulatory agents,</span></p>
<ol>
<li><span style="color: #0000ff;">• such as interferon-alpha.</span></li>
<li><span style="color: #0000ff;">• Antiangiogenesis agents (ie,bevacizumab), which work by disrupting the formation of blood vessels that feed tumors, are a new class of drugs that may prove to be of benefit in the treatment of hepatocellular carcinoma.</span></li>
<li><span style="color: #0000ff;"> • Sorafenib, a multitargeted oral kinase inhibitor, has recently been shown in a phase III trial to prolong survival in patients with hepatocellular carcinoma.<br />
</span></li>
<li><span style="color: #0000ff;"> Sunitinib<br />
Erlotinib</span></li>
</ol>
<p style="text-align: justify;"><span style="color: #0000ff;"><br />
• <span style="color: #ff6600;">Embolizing agents </span>such as cellulose, microspheres, lipoidal, and gelatin foam particles are used to deliver intra-arterial chemotherapy (mitomycin, doxorubicin, cisplatin) to the tumor via the hepatic artery.<br />
</span></p>
<p style="text-align: justify;"><span style="color: #0000ff;">• <span style="color: #ff6600;">Partial hepatectomy<br />
</span></span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">• Orthotopic liver transplantation </span>can be considered for patients.</span></p>
<p style="text-align: justify;"><span style="color: #ff6600;">• Local tumor ablation</span><span style="color: #0000ff;"> </span></p>
<p style="text-align: justify;"><span style="color: #0000ff;"><span style="color: #ff6600;">• Intratumoral injections of ethanol or acetic acid, heat (via radiofrequency, microwave, or laser<br />
ablation), or cold (cryoablation with liquid nitrogen) </span>may be used to locally control tumors smaller<br />
than 4-5 cm. These techniques are frequently performed percutaneously as outpatient<br />
procedures. In general, these procedures are reserved for patients who do not meet criteria for<br />
surgical resection yet are candidates for a liver-directed procedure based on the presence of<br />
limited liver-only disease.<br />
<span style="color: #ff6600;">• Radiofrequency ablation (RFA)</span> is the delivery of radiofrequency thermal energy to the<br />
hepatocellular carcinoma lesion causing necrosis of the tumor.<br />
<span style="color: #ff6600;">• Percutaneous ethanol or acetic acid ablation </span>is reserved for patients with small tumors; however,<br />
in many areas, the ease and efficacy of RFA has now replaced these older techniques.<br />
Radiation therapy is limited by dose-related radiation hepatitis, which precludes the<br />
administration of external beam radiation in doses effective for tumor eradication. Doses of 2500<br />
cGy may be used for palliative measures.<br />
<span style="color: #ff6600;">• CyberKnife system</span> is a new technology that uses a combination of robotics and image guidance<br />
to deliver concentrated and highly focused beams of radiation to the tumor while minimizing<br />
radiation exposure to the surrounding healthy liver tissue.</span></p>
<p style="text-align: justify;">
<p style="text-align: right;"><span style="color: #0000ff;"><span style="color: #008000;">Summarized- Source Medscape.com, Bailey and Love&#8217;s manual of surgery, wikipedia, Manipal book of Surgery</span><br />
</span></p><img src="http://medchrome.com/?ak_action=api_record_view&id=1083&type=feed" alt=" Hepatocellular Carcinoma or Liver Cancer"  title="Hepatocellular Carcinoma or Liver Cancer" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/downloads/presentations/hepatocellular-carcinoma-or-liver-cancer/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Antibiotic Resistance and factors for it &#8211; Presentation</title>
		<link>http://medchrome.com/basic-science/microbiology/antibiotic-resistance-and-factors-for-it-presentation/</link>
		<comments>http://medchrome.com/basic-science/microbiology/antibiotic-resistance-and-factors-for-it-presentation/#comments</comments>
		<pubDate>Thu, 27 May 2010 19:24:57 +0000</pubDate>
		<dc:creator>Sulav Shrestha</dc:creator>
				<category><![CDATA[Microbiology]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[Downloads]]></category>
		<category><![CDATA[ppt]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=1049</guid>
		<description><![CDATA[OBJECTIVES

• To Define Antibiotic Resistance.
• To Discuss Various Factors Affecting Antibiotic Resistance


Antibiotic &#38; Antibiotic Resistance
• Antibiotic: any of various chemical substances,produced by various microorganisms, esp. fungi, or made synthetically and capable of destroying or inhibiting the growth of microorganism.
• People may exhibit allergic reactions to antibiotics, but they are not resistant to them. It is the bacteria themselves, not the infected host, which become resistant.
Antibiotic ...]]></description>
			<content:encoded><![CDATA[<p><span style="color: #0000ff;"><strong><span style="color: #ff6600;">OBJECTIVES</span></strong></span></p>
<ol>
<li><span style="color: #0000ff;">• To Define Antibiotic Resistance.</span></li>
<li><span style="color: #0000ff;">• To Discuss Various Factors Affecting Antibiotic</span><span style="color: #0000ff;"><span style="color: #ff6600;"><strong> <span style="color: #0000ff;"><span style="font-weight: normal;">Resistance</span></span></strong></span></span></li>
</ol>
<p><a href="http://medchrome.com/wp-content/uploads/2010/05/antibiotic-resistance-cartoon.jpg"><img class="aligncenter size-full wp-image-1050" title="antibiotic resistance cartoon" src="http://medchrome.com/wp-content/uploads/2010/05/antibiotic-resistance-cartoon.jpg" alt="antibiotic resistance cartoon Antibiotic Resistance and factors for it   Presentation" width="575" height="423" /></a></p>
<p><span style="color: #ff6600;"><strong>Antibiotic &amp; Antibiotic Resistance</strong></span></p>
<p><span style="color: #0000ff;">• Antibiotic: any of various chemical substances,produced by various microorganisms, esp. fungi, or made synthetically and capable of destroying or inhibiting the growth of microorganism.</span></p>
<p><span style="color: #0000ff;">• People may exhibit allergic reactions to antibiotics, but they are not resistant to them. It is the bacteria themselves, not the infected host, which become resistant.</span></p>
<p><span style="color: #ff6600;"><strong>Antibiotic Resistance</strong></span></p>
<p><span style="color: #0000ff;"> <strong>Antibiotic Resistance</strong>: the ability of bacteria and other microorganisms to withstand an antibiotic to which they </span></p>
<p><span style="color: #0000ff;">were once sensitive</span></p>
<p><span style="color: #0000ff;"> <strong>Tolerance</strong> of micro-organisms to inhibitory action of antibiotics.</span></p>
<p><span style="color: #0000ff;"> <strong>Resistance to antibiotics</strong> is a biological phenomenon that can be accelerated by a variety of factors, including human practices.</span></p>
<p><span style="color: #0000ff;"> Resistance Can be: Drug Tolerance, Drug Destruction, Drug Impermeability, Cross resistance.</span></p>
<p><span style="color: #0000ff;">Antibiotic Resistance Is A Serious Worldwide Problem</span></p>
<p><span style="color: #0000ff;">• The monetary cost of treating antibiotic resistant infections worldwide is estimated to be many billions of dollars per year.</span></p>
<p><span style="color: #0000ff;">• According to the researchers : the resistance to antibiotics is increasing at a faster pace than it can be controlled.</span></p>
<p><span style="color: #0000ff;">• Since antibiotic resistance can pass from bacterium to bacterium and resistant bacterial infections can pass from </span></p>
<p><span style="color: #0000ff;">person to person. Thus, antibiotic use and antibiotic resistance can eventually affect an entire community.</span></p>
<p><span style="color: #0000ff;"><strong><span style="color: #ff6600;">Factors Affecting Antibiotic Resistance</span></strong></span></p>
<p><span style="color: #0000ff;"><strong>• Patient’s incompliance to recommended treatment</strong></span></p>
<p><span style="color: #0000ff;">– Forget to take medication</span></p>
<p><span style="color: #0000ff;">– Interrupt their treatment when they begin to feel better</span></p>
<p><span style="color: #0000ff;">– May be unable to afford full course</span></p>
<p><span style="color: #0000ff;">– May also be due to inadequate physician patient interaction</span></p>
<p><span style="color: #0000ff;"><strong>• Irrational use of antibiotics in humans</strong></span></p>
<p><span style="color: #0000ff;">– Self-medication (Unnecessary, Inadequate dose )</span></p>
<p><span style="color: #0000ff;">– Misuse ( Easy availability in pharmacies without prescription )Factors Affecting Antibiotic </span></p>
<p><span style="color: #0000ff;"><strong>• Physicians:</strong></span></p>
<p><span style="color: #0000ff;">– Over prescribing of broad spectrum drugs when narrow spectrum are appropriate</span></p>
<p><span style="color: #0000ff;">– Wrong prescription and guidelines from unskilled practitioners</span></p>
<p><span style="color: #0000ff;">– Unnecessary prescriptions common in private practitioners</span></p>
<p><span style="color: #0000ff;"><strong>• Hospitals :</strong></span></p>
<p><span style="color: #0000ff;">– Nosocomial infections with highly resistant bacterial pathogens.</span></p>
<p><span style="color: #0000ff;">– Mainly due to poor infection control practices like handwashing, changing gloves, etc. </span></p>
<p><span style="color: #0000ff;"><strong>• Poor Quality Of Antibiotics:</strong></span></p>
<p><span style="color: #0000ff;">– Expired and counterfeit antibiotics</span></p>
<p><span style="color: #0000ff;">– Due to lack of quality compliance and monitoring</span></p>
<p><span style="color: #0000ff;"><strong>• Irrational Use Of Antibiotics In Animals</strong></span></p>
<p><span style="color: #0000ff;">– Used for growth and disease control in poultry, cattle, pigs, etc.</span></p>
<p><span style="color: #0000ff;">– We are indirectly taking these antibiotics when we are eating these animals.</span></p>
<p><span style="color: #0000ff;"><strong>• Inadequate Surveillance &amp; Susceptibility Testing:</strong></span></p>
<p><span style="color: #0000ff;">– Unknown susceptibility pattern of bacterial isolates encourages empirical selection of broad spectrum antibiotics.</span></p>
<p><span style="color: #0000ff;">– Due to lack of equipment and personnel.</span></p>
<p><span style="color: #0000ff;"><strong>• Crowding/Travel of People &amp; Unhygienic Conditions:</strong></span></p>
<p><span style="color: #0000ff;">– Residents of developing countries often carry antibiotic-resistant fecal commensal organisms . Visitors to developing countries passively acquire antibiotic-resistant E.coli, even if they are not taking prophylactic antibiotics, which suggests that they encounter a reservoir of antibiotic-resistant strains during travel.</span></p>
<p><span style="color: #ff6600;"><strong>Summary</strong></span></p>
<p><span style="color: #0000ff;">• <span style="color: #008000;">Developing prescription guidelines, Emphasizing on public awareness, emphasizing quality compliance and monitoring of antibiotics manufactured or dispensed, public sanitation, improved hospital infection control are some of the measures to be taken to combat the growing problem of Antibiotic Resistance.</span></span></p>
<div id="__ss_3755447" style="width: 425px;"><strong><a title="Antibiotic resistance" href="http://www.slideshare.net/sulavmetal/antibiotic-resistance">Antibiotic resistance</a></strong><object id="__sse3755447" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="425" height="355" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="allowFullScreen" value="true" /><param name="allowScriptAccess" value="always" /><param name="src" value="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=antibioticresistance-100417005953-phpapp01&amp;stripped_title=antibiotic-resistance" /><param name="name" value="__sse3755447" /><param name="allowfullscreen" value="true" /><embed id="__sse3755447" type="application/x-shockwave-flash" width="425" height="355" src="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=antibioticresistance-100417005953-phpapp01&amp;stripped_title=antibiotic-resistance" name="__sse3755447" allowscriptaccess="always" allowfullscreen="true"></embed></object></p>
<div style="padding: 5px 0 12px;">View more <a href="http://www.slideshare.net/">presentations</a> from <a href="http://www.slideshare.net/sulavmetal">Sulav Shrestha</a>.</div>
</div>
<p><span style="color: #0000ff;"><span style="color: #008000;"><span style="color: #800000;">Sources:</span></span></span></p>
<ul>
<li><span style="color: #800000;">• <a href="http://www.cdc.gov" rel="nofollow" target="_blank">http://www.cdc.gov</a></span></li>
<li><span style="color: #800000;">• <a href="http://www.who.int/en" rel="nofollow" target="_blank">http://www.who.int/en</a></span></li>
</ul>
<ul>
<li><span style="color: #0000ff;">Prepared By:</span></li>
<li><span style="color: #0000ff;">• Srijana Shakya (79)</span></li>
<li><span style="color: #0000ff;">• Sulabh Shrestha (80)</span></li>
<li><span style="color: #0000ff;">• Surakshya Rayamajhi (81)</span></li>
<li><span style="color: #0000ff;">• Surendra Pariyar (82)</span></li>
<li><span style="color: #0000ff;">• Sushil Dulal (83)</span></li>
<li><span style="color: #0000ff;">• Sushmita Sharma (84)</span></li>
</ul><img src="http://medchrome.com/?ak_action=api_record_view&id=1049&type=feed" alt=" Antibiotic Resistance and factors for it   Presentation"  title="Antibiotic Resistance and factors for it   Presentation" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/basic-science/microbiology/antibiotic-resistance-and-factors-for-it-presentation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ALCOHOL RELATED DISORDER</title>
		<link>http://medchrome.com/downloads/presentations/alcohol-related-disorder/</link>
		<comments>http://medchrome.com/downloads/presentations/alcohol-related-disorder/#comments</comments>
		<pubDate>Wed, 09 Dec 2009 16:19:55 +0000</pubDate>
		<dc:creator>drsaurav</dc:creator>
				<category><![CDATA[Hepatobiliary]]></category>
		<category><![CDATA[Presentations]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[alcoholic diseases]]></category>
		<category><![CDATA[ALD]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=339</guid>
		<description><![CDATA[ALCHOHOL RELATED DISORDER 
 
 
ALCOHOL  are hydroxy derivatives of aliphatic hydrocarbons.
MANUFACTURE:-
 Zymase
C6H12 O6&#8212;&#8212;&#62; 2 CO2+ 2C 2 H 5 OH
 (sugar)&#8212;-&#62; (in yeast) 
 
METABOLISM OF ALCOHOL

Alcohol is metabolized in liver by alcohol dehydrogenase

90% &#8211; processed in liver.
10% &#8211; excreted (eliminated unchanged
from kidneys and lungs)

Absorption 10% from stomach.

Mostly from small intestine.
Peak effect in 30 to 90 min (empty stomach ...]]></description>
			<content:encoded><![CDATA[<h2><strong><span style="color: #ff0000;">ALCHOHOL RELATED DISORDER </span></strong></h2>
<p><strong><span style="color: #ff0000;"> </span></strong></p>
<div id="attachment_351" class="wp-caption aligncenter" style="width: 460px"><strong><img class="size-full wp-image-351" title="Beer cheers" src="http://medchrome.com/wp-content/uploads/2009/12/beer_toast1.jpg" alt="Alcohol a social need or problem?" width="450" height="338" /></strong><p class="wp-caption-text">Alcohol a social need or problem?</p></div>
<p><strong> </strong></p>
<p>ALCOHOL  are hydroxy derivatives of aliphatic hydrocarbons.</p>
<p>MANUFACTURE:-</p>
<p><strong> Zymase</strong></p>
<p><strong>C6H12 O6&#8212;&#8212;&gt; 2 CO2+ 2C 2 H 5 OH</strong></p>
<p><strong> (sugar)&#8212;-&gt; (in yeast) </strong></p>
<p><strong> </strong></p>
<p><strong><span style="color: #ff00ff;">METABOLISM OF ALCOHOL</span></strong></p>
<ul>
<li>Alcohol is metabolized in liver by alcohol dehydrogenase</li>
</ul>
<p>90% &#8211; processed in liver.</p>
<p>10% &#8211; excreted (eliminated unchanged</p>
<p>from kidneys and lungs)</p>
<ul>
<li>Absorption 10% from stomach.</li>
</ul>
<p>Mostly from small intestine.</p>
<p>Peak effect in 30 to 90 min (empty stomach 30 to 60 min)</p>
<p>Depends  upon:</p>
<ul>
<li> time of food intake.</li>
<li>duration of consumption.</li>
<li>type of drink consumed.</li>
</ul>
<p><strong> alc. DHASE &#8212;&#8211;                                                ald. DHASE </strong></p>
<p><strong>Alcohol&#8212;&#8212;&#8212;&#8212;&gt;acetaldehyde&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-&gt;acetic acid &#8212;&#8212;&#8211;&gt;CO2+ H2O</strong></p>
<p><strong> </strong></p>
<p><strong> </strong></p>
<p><strong><span style="color: #ffcc00;">CONCENTRATION OF ALCOHOL IN DIFFERENT LIQUORS</span></strong></p>
<p>Beer :- 4 &#8211; 8%</p>
<p>Wine :- 12 %</p>
<p>Whisky and other liquors:- 40%</p>
<p>Illicit:- 20 &#8211; 40 %</p>
<p>1 unit = 30 ml of whisky or 360 ml of beer or 120 ml of wine</p>
<p>In 70 kg person 1 unit gives 15 &#8211; 20 mg/ dl of blood level</p>
<p>SAFE DRINKING:- MEN :- 21 unit/ week</p>
<p>WOMEN :- 14 unit / week</p>
<p><strong><span style="color: #ff6600;">CALORIC VALUES OF ALCOHOL</span></strong></p>
<p>1) Alcohol is full of calories</p>
<p>2) 2 &#8211; 3 gin and tonic/day for 4 wks will increase wt about 4 pounds.</p>
<p>3) 1 pint of beer = 1000- 2000 kcal</p>
<p><strong> </strong></p>
<p><strong><span style="color: #993300;">DETERMINANTS OF BAC</span></strong></p>
<ol>
<li>Quantity/ speed of drinking.</li>
<li>Concn of alcohol in the drink.</li>
<li>Body fat (W BAC 20 % &gt; M)</li>
<li>Addition of soda carbonated beverage.</li>
<li> empty stomach.</li>
<li>Body wt:- higher the� body wt lower the BAC.</li>
<li>Carbohydrate food in stomach delays      absorption.</li>
</ol>
<p><strong>BAC mg/dl&#8212;&#8211;Behavioral correlates </strong></p>
<p>&lt; 80&#8212; Euphoria, feeling of relaxation, talking freely, reduced alertness</p>
<p>&gt;80&#8212; Noisy , moody , impaired judgment</p>
<p>100- 200&#8212; blurred vision , unsteady gate, gross motor incordination , slurred speech, aggressive</p>
<p>Quarrelsome and talking loudly.</p>
<p>200 &#8211; 300&#8212;Amnesia for experience( alcoholic blackout)</p>
<p>300 &#8211; 350&#8212; coma</p>
<p>350 &#8211; 600&#8212;&#8211; death</p>
<p><strong><span style="color: #99cc00;">LEVELS OF ALCOHOL USE</span></strong></p>
<p>SOCIAL USE:- without any apparent harm, exploration for curiosity, group activity, to relieve anxiety, dissolve inhibition, facilitate social interaction , dietary practice religious rituals.</p>
<p>HARMFUL USE/ ABUSE:- leads to impairment in one of more areas of daily life ( physical , social , occupational , family life, legal involvement)</p>
<p>ALCOHOL DEPENDANCE:-Feeling of compelled to drink,</p>
<p>A stereotyped pattern of drinking</p>
<p>Alcohol takes priority over anything else.</p>
<p>Development of tolerance</p>
<p>Psychological and physical withdrawal symp.</p>
<p>Relief after drinking</p>
<p><strong><span style="color: #008000;">ICD&#8217;s 10 criteria for substance abuse</span></strong></p>
<p>a pattern of psychoactive substance use that is causing damage to health; the damage may be to physical or mental health.</p>
<p><strong><span style="color: #00ff00;">ICD&#8217;s 10 criteria for substance dependence</span></strong></p>
<p>Three or more of the following must have been experienced or exhibited at some time during the previous year:</p>
<p>1. <strong>Difficulties in controlling substance-taking behavior </strong>in terms of its onset, termination, or levels of use</p>
<p>2. A <strong>strong desire</strong> or sense of compulsion to take the substance</p>
<p>3. <strong>Progressive neglect of alternative pleasures or interests </strong>because of psychoactive substance use, increased amount of time necessary to obtain or take the substance or to recover from its effects</p>
<p>4. <strong>Persisting with substance use despite clear evidence of overtly harmful consequences</strong>, depressive mood states consequent to heavy use, or drug related impairment of cognitive functioning</p>
<p>5. <strong>Evidence of tolerance</strong>, such that increased doses of the psychoactive substance are required in order to achieve effects originally produced by lower doses</p>
<p>6. <strong>A physiological withdrawal state </strong>when substance use has ceased or been reduced, as evidence by: the characteristic withdrawal syndrome for the substance; or use of the same (or a closely related) substance with the intention of relieving or avoiding withdrawal symptoms.</p>
<p><strong> </strong></p>
<p><strong> </strong></p>
<p><strong><span style="color: #0000ff;">CAGE QUESTIONNAIRE FOR DIAGNOSIS OF ALCOHOLICS</span></strong></p>
<p><strong>C- </strong>Have you ever tried to <strong>C</strong>ut down on alcohol (amount)?</p>
<p><strong>A- </strong>Have you ever been <strong>A</strong>nnoyed by people&#8217;s criticism of alcoholism?</p>
<p><strong>G- </strong>Have you ever felt <strong>G</strong>uilty about drinking?</p>
<p><strong>E- </strong>Have you ever needed an <strong>E</strong>ye opener drink (early morning drink)?</p>
<p>A SCORE OF 2 OR &gt; IDENTIFIES PROBLEM DRINKER.</p>
<p><span style="color: #33cccc;">CLINICAL FEATURES</span></p>
<p>Symptoms:-</p>
<p>1) Neglect of other activities.(social, occupational , recreational)</p>
<p>2) Excessive use:- consumed in large amount over a long period of time.</p>
<p>3) Impaired control of drinking habit.</p>
<p>4) Persistence of use inspite of physical or psychological problem created by it.</p>
<p>5) Large amount of time spent in alcohol related activities.</p>
<p>6) Withdrawal symptoms:- N/V, shaking, sweating, anxiety</p>
<p>7) Tolerance:- need of increasing amount of alcohol to feel its effect.</p>
<p><strong><span style="color: #ff0000;">COMPLICATION</span></strong></p>
<p><strong>MEDICAL COMPLICATION</strong></p>
<p>GI:- gastritis, reflux oesophagitis, esophageal avarices, peptic ulcer, ca stomach and stomach, malabsorption syndrome, pancreatitis.</p>
<p>HEPATO:- fatty liver, cirrhosis of liver, hepatitis, ca liver.</p>
<p>CNS:- peripheral neuropathy, delirium tremens , rum fits, alcoholic hallucinosis , wernicke- korsakoff psychosis, alcoholic dementia, cerebellar degeneration, alcoholic myopathy, suicide</p>
<p>CVS:- Cardiomyopathy, hypertension.</p>
<p>HEMATOLOGICAL:- anemia, leucopenia, decrease platelet and increase MCV</p>
<p>METABOLIC:- ketoacidosis, hypoglycemia, hypocalcaemia, hypomagnesaemia</p>
<p>MISCELLANEOUS:- Osteoporosis, psoriasis, fetal alcohol syndrome, impotence decrease immunity etc.</p>
<p><strong>SOCIAL COMPLICATION:-</strong></p>
<p>Accidents, marital disharmony, divorce, occupational problems,increase incidence of drug dependance, criminality, financial difficulties.</p>
<p><strong><span style="color: #ff0000;">ACUTE ALCOHOL INTOXICATION </span></strong></p>
<p>Brief period of excitement then generalized CNS depression.</p>
<p>Increased reaction time, slowed thinking, distractibility, and poor motor control.</p>
<p>Later , dysarthria , ataxia and in coordination, progressive loss of self control.</p>
<p><strong> </strong></p>
<p><strong><span style="color: #ff0000;">ALCOHOL WITHDRAWAL SYNDROM </span></strong></p>
<p>Abrupt cessation or rapid decrease in amount of alcohol consumption causes:</p>
<p>1 MINOR WITHDRAWAL SYMPTOMS:- (12 &#8211; 18 hrs)</p>
<p>tremors, nausea/ vomiting, tachycardia, HTN, weakness, anxiety, insomnia.</p>
<p>2) MAJOR WITHDRAWAL SYMPTOMS:- (7 &#8211; 36 hrs)</p>
<p>a) Delirium tremens</p>
<p>b) Alcoholic seizure (rum fits)</p>
<p>c) Alcoholic hallucinosis.</p>
<p><strong><span style="color: #ff0000;">DELIRIUM TREMENS </span></strong></p>
<ul>
<li>Severe withdrawal syndrome, life threatening</li>
<li>Starts 2- 3 days after cessation of alcohol intake and features last for 3 &#8211; 7 days.</li>
<li>Acute organic brain syndrome with feature of :-</li>
<li>Clouding of consciousness with Disorientation in time , place, person</li>
<li>Poor attention span and distractibility.</li>
<li>Visual , auditory hallucination, tactile hallucination, illusion , delirium.</li>
<li>Autonomic disturbance:- tachycardia, sweating, fever, HTN, pupillary dilatation</li>
<li>Psychomotor agitation, ataxia</li>
<li> insomnia</li>
<li>Dehydration with electrolyte imbalance</li>
</ul>
<p><strong><span style="color: #ff0000;">ALCOHOLIC SEIZURES ( RUM FITS) </span></strong></p>
<ul>
<li><strong>Generalized tonic clonic seizures </strong>occur in about 10% of alcohol dependence ptn. After 12- 48 hrs after cessation or decrease in amount of alcohol.</li>
<li><strong>Multiple seizures </strong>(2-6 at one time) common than single seizures.</li>
<li>ALCOHOLIC HALLUCINOSIS</li>
<li>Usually <strong>auditory hallucination </strong>during partial or complete abstinence following regular alcohol intake. In 2% ptn.</li>
<li>Persists after the withdrawal syndrome is over and classically occurs in clear consciousness.</li>
<li>Usually recovery occurs within one month and the duration is very rarely &gt; 6 months.</li>
</ul>
<p><strong><span style="color: #ff0000;">WERNICKE�S ENCEPHALOPATHY </span></strong></p>
<ul>
<li>This is an acute reaction to severe def of thiamin.</li>
<li>Imp clinical signs:-</li>
<li>Ocular signs:- <strong>nystagmus</strong>, ophthalmoplegia,b/l external rectus paralysis, pupilary irregularities, retinal hemorrhages and papiloedema</li>
<li>HMF disturbances:- disorientation, <strong>confusion</strong>, recent memory disturbances, poor attention span and distractibility, apathy and <strong>ataxia. </strong></li>
</ul>
<p><strong><span style="color: #ff0000;">KORSAKOFF�S PSYCHOSIS </span></strong></p>
<ul>
<li>Follows wernicke&#8217;s encephalopathy</li>
<li>Together refered as wernicke&#8217;s korsakoff&#8217;s psychosis.</li>
<li>Cause:- severe, untreated thiamin deficiency secondary to chronic alcohol use.</li>
<li>Clinically presents as organic amnestic syndrome characterized by gross memory impairement( anterograde amnesia )and confabulation.</li>
</ul>
<p><span style="color: #ff6600;"><strong>TREAMENT </strong></span></p>
<p><span style="color: #ff6600;">BEFORE TREATMENT:-</span></p>
<ul>
<li><span style="color: #008000;">Rule out physical disorder, psychiatric disorder,</span></li>
<li><span style="color: #008000;">Assessment of motivation for treatment.</span></li>
<li><span style="color: #008000;">Assessment of social support system</span></li>
<li><span style="color: #008000;">Assessment of personality characteristics of the patient</span></li>
<li><span style="color: #008000;">Assessment of the current and past social interpersonal and occupational functioning.</span></li>
</ul>
<p><span style="color: #008000;"><strong> </strong></span></p>
<p><span style="color: #ff6600;"><strong>DETOXIFICATION in hospital for 7 to 14 days:- </strong></span></p>
<p><span style="color: #008000;">BENZODIAZEPINES:-</span></p>
<p><span style="color: #008000;">CHLORDIAZEPOXIDE (80 &#8211; 200 Mg/day in divided dose).</span></p>
<p><span style="color: #008000;">DIAZEPAM( 40 &#8211; 80 Mg/day in divided dose)</span></p>
<p><span style="color: #008000;">CARBAMAZEPINE ( 600  -1600 Mg/ day)</span></p>
<p><span style="color: #008000;">IV THIAMIN 100 mg bid for 3 &#8211; 5 days followed by oral admin of B1 for at least 6 month.</span></p>
<p><span style="color: #008000;">GOOD NUTRITION with vitamin B,C, A supplements.</span></p>
<p><span style="color: #008000;"><strong> </strong></span></p>
<p><span style="color: #ff6600;"><strong>ALCOHOL DEPENDENCE:-</strong></span></p>
<p><span style="color: #008000;">BEHAVIOURAL THERAPY:-</span></p>
<p><span style="color: #008000;">PSYCHOTHERAPY:-</span></p>
<p><span style="color: #008000;">DETERRENT AGENTS<strong>:- </strong></span></p>
<p><span style="color: #008000;">DISULFIRAM 250- 500mg/day at bedtimes for 1 wk, then 250 mg/ day maintenance dose.</span></p>
<p><span style="color: #008000;">.</span></p>
<p><span style="color: #008000;"><strong> </strong></span></p>
<p><span style="color: #008000;"><strong> </strong></span></p>
<p><span style="color: #008000;"><strong> </strong></span></p>
<p><span style="color: #ff6600;"><strong>ANTI- CRAVING AGENT:-</strong></span></p>
<ul>
<li><span style="color: #008000;">ACAMPROSATE</span></li>
<li><span style="color: #008000;">NALTREXONE:-</span></li>
<li><span style="color: #008000;">FLUOXETNE:-</span></li>
</ul>
<p><span style="color: #008000;"><span style="color: #ff6600;"><strong>OTHERS</strong>:-</span> benzodiazepines, antidepressants, antipsychotics, lithium, carbamazepine, narcotics for special use.</span></p>
<p><span style="color: #ff6600;"><strong>PSYCHOSOCIAL REHABILITATION:-</strong></span></p>
<p><span style="color: #ff6600;"><strong>TREATMENT OF WITHDRAWAL SYNDROMES:-</strong></span></p>
<p><span style="color: #ff6600;">v� <strong>Minor withdrawal:- </strong></span></p>
<p><span style="color: #008000;">T/T:- chlordiazepoxide or oxazepam.</span></p>
<p><span style="color: #ff6600;">v� <strong>Major withdrawal:-</strong></span></p>
<p><span style="color: #008000;">Delirium Tremens:-</span></p>
<p><span style="color: #008000;">T/T:- iv benzodiazepines and</span></p>
<p><span style="color: #008000;">supportive care nutrition, electrolyte balance, vit B complex.</span></p>
<p><span style="color: #008000;">Alcoholic seizures:-</span></p>
<p><span style="color: #008000;">T/T:- iv benzodiazepines</span></p>
<p><span style="color: #008000;">Alcoholic hallucinosis:-</span></p>
<p><span style="color: #008000;">T/T:- neuroleptics ( haloperidol 2 &#8211; 5 mg bid)</span></p>
<p><span style="color: #008000;">Wernickes encephalopathy:-</span></p>
<p><span style="color: #008000;">T/T:- inj of thiamine( 100 mg IM)</span></p><img src="http://medchrome.com/?ak_action=api_record_view&id=339&type=feed" alt=" ALCOHOL RELATED DISORDER"  title="ALCOHOL RELATED DISORDER" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/downloads/presentations/alcohol-related-disorder/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
		</item>
		<item>
		<title>DISSOCIATIVE DISORDER</title>
		<link>http://medchrome.com/downloads/presentations/dissociative-disorder/</link>
		<comments>http://medchrome.com/downloads/presentations/dissociative-disorder/#comments</comments>
		<pubDate>Wed, 09 Dec 2009 15:57:20 +0000</pubDate>
		<dc:creator>drsaurav</dc:creator>
				<category><![CDATA[Presentations]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[Dissociative Disorder]]></category>

		<guid isPermaLink="false">http://medchrome.com/?p=336</guid>
		<description><![CDATA[DISSOCIATIVE DISORDER
 


 Dissociative disorder:- (conversion disorder)
is a partial or complete loss of the normal integration between memories of the past, awareness of identity and immediate sensations, and control of bodily movements.
Previously known as conversion hysteria.
EPIDEMIOLOGY:-
According to DSM-IV-TR ( 11 to 500 cases per 100,000 population)
Women :men (adult ) 2-10:1 and among children there is higher predominance in girls.
Most common ...]]></description>
			<content:encoded><![CDATA[<p><strong><span style="color: #ff0000;">DISSOCIATIVE DISORDER</span></strong></p>
<p><strong><span style="color: #ff0000;"> </span></strong></p>
<p><strong></p>
<div id="attachment_356" class="wp-caption aligncenter" style="width: 510px"><img class="size-full wp-image-356" title="4053915392_b2be2b8d00" src="http://medchrome.com/wp-content/uploads/2009/12/4053915392_b2be2b8d00.jpg" alt="Mind Games" width="500" height="327" /><p class="wp-caption-text">Mind Games</p></div>
<p></strong></p>
<p><span style="color: #993366;"> Dissociative disorder:- (conversion disorder)</span></p>
<p>is a partial or complete loss of the normal integration between memories of the past, awareness of identity and immediate sensations, and control of bodily movements.</p>
<p>Previously known as conversion hysteria.</p>
<p><strong><span style="color: #00ffff;">EPIDEMIOLOGY:-</span></strong></p>
<p>According to DSM-IV-TR ( 11 to 500 cases per 100,000 population)</p>
<p>Women :men (adult ) 2-10:1 and among children there is higher predominance in girls.</p>
<p>Most common in rural populations, people with little education, those with low IQ, in low socio economic groups and military personnel exposed to combat situation. And commonly associated with major depressive disorder, anxiety disorder and schizophrenia.</p>
<p><strong> </strong></p>
<p><strong><span style="color: #ff6600;">ETIOLOGY:-</span></strong></p>
<p>PSYCHOANALYTIC FACTOR:-repression of unconscious intrapsychic conflict and the conversion of anxiety into a physical symptom.</p>
<p>BEHAVIOURAL THEORY:-symptoms are learned response in the face of stress.</p>
<p>BIOLOGICAL THEORY:- hypofunction of the dominant hemisphere</p>
<p><strong> </strong></p>
<p><span style="color: #993366;"><strong>CLINICAL FEATURE:-</strong></span></p>
<p>MOTOR SYMPTOMS:- abnormal movements, gait disturbance(astasia abasia), weakness and paralysis. Gross rhythmical tremors, choreiform movements, tics and jerks may be present.</p>
<p>SENSORY SYMPTOMS:- anesthesia and paresthesia are common.</p>
<p>May involve the organs of special symptoms ( deafness, blindness, tunnel vision)</p>
<p>SEIZURE SYMPTOMS:- especially pseudo seizure, which can be differentiated by typical symptoms like non- stereotypical clinical pattern , occurs usually in indoor safe place, tongue bit/ incontinence rarely present, duration of episode longer, neurological sign is absent, EEG is normal, serum prolactin increased.</p>
<p><span style="color: #993366;"> OTHER ASSOCAITED FEATURES:-</span></p>
<ul>
<li> PRIMARY GAIN:</li>
<li> SECONDARY GAIN:</li>
<li> LA BELLE INDIFFERENCE:-</li>
<li> IDENTIFICATION:-</li>
</ul>
<p><strong><span style="color: #008000;">CLASSIFICATION:-ICD 10 (F44) </span></strong></p>
<p>F44.0 DISSOCIATIVE AMNESIA</p>
<p>F44.1 DISSOCIATIVE FUGUE</p>
<p>F44.2 DISSOCIATIVE STUPOR</p>
<p>F44.3 TRANCE AND POSSESSION DISORDER</p>
<p>F44.4-44.7DISSOCIATIVE DISORDERS OF MOVEMENTS AND SENSATION</p>
<p>44.4 DISSOCIATIVE MOTOR DISORDERS</p>
<p>44.5 DISSOCIATIVE CONVULSIONS</p>
<p>44.6 DISSOCIATIVE ANAESTHESIA AND SENSORY LOSS</p>
<p>44.7 MIXED DISSOCIATIVE(CONVERSION ) DISORDER.</p>
<p>44.8 OTHERS DISSOCIATIVE(CONVERSION) DISORDER.</p>
<p>44.9 DISSOCIATIVE (CONVERSION) DISORDER, UNSPECIFIED</p>
<p><strong><span style="color: #00ff00;">DIAGNOSTIC GUIDELINES OF DISSOCIATIVE DISORDER :-ICD-10</span></strong></p>
<p>A) the clinical features as specified for the individual disorders in F44.</p>
<p>B) no evidence of a physical disorder that might explain the symptoms.</p>
<p>C) evidence for psychological causation, in the form of clear association in time with stressful events and problems or disturbed relationship (even if denied by the individual)</p>
<p><strong><span style="text-decoration: underline;"> </span></strong></p>
<p><strong><span style="text-decoration: underline;"> </span></strong></p>
<p><strong><span style="text-decoration: underline;"> </span></strong></p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">F44.0 DISSOCIATIVE AMNESIA</span></span></strong></p>
<p>The main feature is loss of memory, usually of important recent events, which is not due to organic mental disorder and is too extensive to be explained by ordinary forgetfulness and fatigue. Usually due to traumatic events( accidents, unexpected bereavements ) and is usually partial and selective.</p>
<p>Several forms are present:-</p>
<p>Localized amnesia:-</p>
<p>Selective amnesia:-</p>
<p>Generalized amnesia:-</p>
<p>Continuous amnesia:-</p>
<p>Systematized amnesia:-</p>
<p><strong>DIAGNOSTIC GUIDELINES (ICD 10)</strong></p>
<p>A) amnesia , either partial or complete, for recent events that are of traumatic or stressful nature(these aspects may emerge only when other informants are available)</p>
<p>B) absence of organic brain disorders, intoxication, or excessive fatigue.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">F44.1� DISSOCIATIVE FUGUE</span></span></strong></p>
<p>All feature of dissociative amnesia + apparent purposeful journey away from home or place of work during which self care is maintained.</p>
<p><strong><span style="color: #000000;">DIAGNOSTIC GUIDELINES( ICD-10)</span></strong></p>
<p>A)the features of dissociative amnesia 44.0</p>
<p>B) purposeful travel beyond the usual everyday range.(differentiation between travel and wandering must be made by those with local knowledge)</p>
<p>C) maintenance of basic self care(eating ,washing) and simple social interaction with strangers( such as buying tickets or petrol, asking directions, ordering meals)</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">F44.2 DISSOCIATIVE STUPOR</span></span></strong></p>
<p>Profound diminution or absence of voluntary movement and normal responsiveness to external stimuli such as light, noise, and touch. They are motionless and mute, but are aware of surroundings.</p>
<p><strong>DIAGNOSTIC CRITERIA (ICD-10)</strong></p>
<p>A) stupor, as described above.</p>
<p>B)Absence of a physical or other psychiatric disorder that might explain the stupor. And</p>
<p>C) evidence of recent stressful events or current problems.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">F44.3 TRANCE AND POSSESSION DISORDER</span></span></strong></p>
<p>Temporary loss of both the sense of personal identity and full awareness of the surrounding, sometime may even act as if taken over by another personality, spirit, deity, or a force.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">F44.4-44.7 DISSOCIATIVE DISORDERS OF MOVEMENTS AND SENSATI<span style="color: #ff0000;">O</span></span><span style="color: #ff0000;">N</span></span></strong></p>
<p>There is loss or interference of movements or loss of sensation.</p>
<p><span style="color: #993366;"> DIAGNOSTIC GUIDELINES:-</span></p>
<p>A) there should be no evidence of physical disorder.</p>
<p>B) sufficient must be known about psychological and social setting and personal relationships of the patients to allow a convincing formulation to be made of the reasons for the appearance of the disorder.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">44.4 DISSOCIATIVE MOTOR DISORDERS</span></span></strong><strong> </strong></p>
<p>Loss of ability to move whole or a part of limb or limbs.</p>
<p>Paralysis may be partial , with movements being weak or slow or complete.</p>
<p>Ataxia ,bizarre gait (astasia abasia), trembling of part or whole body.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">44.5 DISSOCIATIVE CONVULSIONS</span></span></strong></p>
<p>Pseudo seizures present.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">44.6 DISSOCIATIVE ANAESTHESIA AND SENSORY LOSS</span></span></strong></p>
<p>Presence of anesthetic areas of skin with boundaries.</p>
<p>Sensory loss may be accompanied by complaints of par aesthesia.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">44.7 MIXED DISSOCIATIVE(CONVERSION )  DISORDER.</span></span></strong></p>
<p><span style="color: #ff0000;"> </span></p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">44.8 OTHERS DISSOCIATIVE(CONVERSION)  DISORDER.</span></span></strong></p>
<p><span style="color: #000000;"> F44.80 G</span><span style="color: #000000;">anser&#8217;s syndrome: hysterical pseudo dementia (appromixate answer)</span></p>
<p><span style="color: #000000;"> F44.81 Multip</span>le personality disorder</p>
<p>F44.82 Transient dissociative disorder occurring in childhood and adolescence</p>
<p>F44.83 Other specified dissociative disorders.</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">44.9DISSOCIATIVE DISORDER ,UNSPECIFIED </span></span></strong></p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;"> </span></span></strong></p>
<p><strong><span style="text-decoration: underline;"><span style="color: #ff0000;">D/D </span></span></strong></p>
<p>NEUROLOGICAL DISORDER( DEMENTIA, DEGENERATIVE DISORDER)</p>
<p>BRAIN TUMORS, BASAL GANGLIA DISEASES</p>
<p>MYASTHENIA GRAVIS,POLIOMYOSITIS, MYOPATHIES, MULTIPLE SCLEROSIS, GB SYNDROMES.</p>
<p>SCHIZOPHRENIA, DEPRESSIVE DISORDER,AND ANXIETY DISORDER.</p>
<p>SOMATOFORM DISORDER.</p>
<p>MALINGERING AND FACTICIOUS DISORDER,</p>
<p><strong><span style="text-decoration: underline;"><span style="color: #0000ff;">TREATMENT:- </span></span></strong></p>
<p>Resolution is usually spontaneous.</p>
<p><strong><span style="text-decoration: underline;">1) BEHAVIOR THERAPY:-</span></strong></p>
<p>Treat the patient normally, give enough care,actively encourage any improvement in symptomatology.</p>
<p>2)<strong><span style="text-decoration: underline;">PSYCHOTHERAPY WITH ABREACTION </span></strong>Hypnosis , anxiolytics, and behavioral relaxation exercises .</p>
<p>3<strong><span style="text-decoration: underline;">)PSYCHOANALYSIS</span></strong>: To find out conflict and resolve it.</p>
<p>4)<strong><span style="text-decoration: underline;">DRUG THERAPY</span></strong>: iv,thiopentone , amytal or diazepam,</p>
<p><strong> </strong></p>
<p><strong> </strong></p>
<p><strong><span style="color: #993300;">COURSE AND PROGNOSIS </span></strong></p>
<p><span style="color: #993366;"> INITIAL SYMPTOMS </span> 90-100% Resolve within a few days or &lt; a month, 75 %-may not experience another episode but 25% have additional episodes during period of stress.</p>
<p>Prognosis good- if sudden onset, easily identified stress factor, good premorbid adjustment, no comorbid medical or psychiatric disorder.</p>
<p>Prognosis bad- if symptoms persists for longer duration</p><img src="http://medchrome.com/?ak_action=api_record_view&id=336&type=feed" alt=" DISSOCIATIVE DISORDER"  title="DISSOCIATIVE DISORDER" />]]></content:encoded>
			<wfw:commentRss>http://medchrome.com/downloads/presentations/dissociative-disorder/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
